BG63209B1 - Пептиди на антисекреторен фактор регулиращи паталогичните промени на пропускливост - Google Patents

Пептиди на антисекреторен фактор регулиращи паталогичните промени на пропускливост Download PDF

Info

Publication number: BG63209B1
Authority: BG; Bulgaria
Prior art keywords: fragments; seq; nom; amino acids; homologs
Prior art date: 1995-08-24

Application number

BG102280A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG102280A (en

Inventor

Ivar Loennroth

Stefan Lange

Eva Johansson

Eva Jennische

Christina Loennroth

Original Assignee

Rural Patent Svenska Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-24

Filing date

1998-02-24

Publication date

2001-06-29

1998-02-24 Application filed by Rural Patent Svenska Ab filed Critical Rural Patent Svenska Ab

1999-04-30 Publication of BG102280A publication Critical patent/BG102280A/xx

2001-06-29 Publication of BG63209B1 publication Critical patent/BG63209B1/bg

Links

230000001575 pathological effect Effects 0.000 title claims abstract description 13
108010038288 antisecretory factor Proteins 0.000 title abstract description 54
230000035699 permeability Effects 0.000 title description 7
230000001105 regulatory effect Effects 0.000 title description 2
239000012634 fragment Substances 0.000 claims abstract description 60
108090000623 proteins and genes Proteins 0.000 claims abstract description 57
102000004169 proteins and genes Human genes 0.000 claims abstract description 54
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 38
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 38
150000007523 nucleic acids Chemical class 0.000 claims abstract description 15
241001465754 Metazoa Species 0.000 claims abstract description 14
108020004707 nucleic acids Proteins 0.000 claims abstract description 14
102000039446 nucleic acids Human genes 0.000 claims abstract description 14
230000004054 inflammatory process Effects 0.000 claims abstract description 13
206010061218 Inflammation Diseases 0.000 claims abstract description 11
239000013598 vector Substances 0.000 claims abstract description 10
150000001413 amino acids Chemical class 0.000 claims description 59
239000012530 fluid Substances 0.000 claims description 30
230000000694 effects Effects 0.000 claims description 27
238000000034 method Methods 0.000 claims description 21
230000028709 inflammatory response Effects 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
241000251539 Vertebrata <Metazoa> Species 0.000 claims description 5
235000013305 food Nutrition 0.000 claims description 5
241000282412 Homo Species 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 2
239000013543 active substance Substances 0.000 claims description 2
108091008324 binding proteins Proteins 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
230000007935 neutral effect Effects 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 17
102000014914 Carrier Proteins Human genes 0.000 claims 1
108010069898 fibrinogen fragment X Proteins 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 18
206010012735 Diarrhoea Diseases 0.000 abstract description 11
206010030113 Oedema Diseases 0.000 abstract description 4
230000018044 dehydration Effects 0.000 abstract description 4
238000006297 dehydration reaction Methods 0.000 abstract description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
238000010606 normalization Methods 0.000 abstract description 3
102000007079 Peptide Fragments Human genes 0.000 abstract description 2
108010033276 Peptide Fragments Proteins 0.000 abstract description 2
201000010099 disease Diseases 0.000 abstract description 2
239000007788 liquid Substances 0.000 abstract description 2
239000002778 food additive Substances 0.000 abstract 1
235000013373 food additive Nutrition 0.000 abstract 1
239000002299 complementary DNA Substances 0.000 description 29
108010049048 Cholera Toxin Proteins 0.000 description 28
102000009016 Cholera Toxin Human genes 0.000 description 28
108090000765 processed proteins & peptides Proteins 0.000 description 27
241000700159 Rattus Species 0.000 description 26
210000001685 thyroid gland Anatomy 0.000 description 25
230000028327 secretion Effects 0.000 description 18
210000004027 cell Anatomy 0.000 description 15
229940079593 drug Drugs 0.000 description 13
108020001507 fusion proteins Proteins 0.000 description 13
239000013615 primer Substances 0.000 description 13
102000004196 processed proteins & peptides Human genes 0.000 description 13
239000003053 toxin Substances 0.000 description 13
231100000765 toxin Toxicity 0.000 description 13
108700012359 toxins Proteins 0.000 description 13
230000004071 biological effect Effects 0.000 description 12
102000037865 fusion proteins Human genes 0.000 description 12
238000012360 testing method Methods 0.000 description 12
241000283973 Oryctolagus cuniculus Species 0.000 description 11
230000000968 intestinal effect Effects 0.000 description 11
241000588724 Escherichia coli Species 0.000 description 10
238000002347 injection Methods 0.000 description 10
239000007924 injection Substances 0.000 description 10
238000010186 staining Methods 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
210000004556 brain Anatomy 0.000 description 9
210000000813 small intestine Anatomy 0.000 description 9
230000032258 transport Effects 0.000 description 9
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 8
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
108700026244 Open Reading Frames Proteins 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
229960003699 evans blue Drugs 0.000 description 8
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
108091034117 Oligonucleotide Proteins 0.000 description 7
210000001035 gastrointestinal tract Anatomy 0.000 description 7
210000004347 intestinal mucosa Anatomy 0.000 description 7
239000000463 material Substances 0.000 description 7
102000002260 Alkaline Phosphatase Human genes 0.000 description 6
108020004774 Alkaline Phosphatase Proteins 0.000 description 6
102000005720 Glutathione transferase Human genes 0.000 description 6
108010070675 Glutathione transferase Proteins 0.000 description 6
108090000190 Thrombin Proteins 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000000975 dye Substances 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
210000000936 intestine Anatomy 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
239000000243 solution Substances 0.000 description 6
229960004072 thrombin Drugs 0.000 description 6
102100033458 26S proteasome non-ATPase regulatory subunit 4 Human genes 0.000 description 5
229920000936 Agarose Polymers 0.000 description 5
101000995014 Archaeoglobus fulgidus (strain ATCC 49558 / DSM 4304 / JCM 9628 / NBRC 100126 / VC-16) Iron-sulfur flavoprotein AF_1436 Proteins 0.000 description 5
108020004414 DNA Proteins 0.000 description 5
101001135231 Homo sapiens 26S proteasome non-ATPase regulatory subunit 4 Proteins 0.000 description 5
101001001496 Homo sapiens Interferon gamma receptor 2 Proteins 0.000 description 5
238000000636 Northern blotting Methods 0.000 description 5
230000001262 anti-secretory effect Effects 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
238000009826 distribution Methods 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
210000004877 mucosa Anatomy 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
CTRXDTYTAAKVSM-UHFFFAOYSA-N 3-{[ethyl({4-[(4-{ethyl[(3-sulfophenyl)methyl]amino}phenyl)(2-sulfophenyl)methylidene]cyclohexa-2,5-dien-1-ylidene})azaniumyl]methyl}benzene-1-sulfonate Chemical compound C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S(O)(=O)=O)C=CC=1N(CC)CC1=CC=CC(S(O)(=O)=O)=C1 CTRXDTYTAAKVSM-UHFFFAOYSA-N 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
108010024636 Glutathione Proteins 0.000 description 4
108020005187 Oligonucleotide Probes Proteins 0.000 description 4
101710084578 Short neurotoxin 1 Proteins 0.000 description 4
101710182532 Toxin a Proteins 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
238000001042 affinity chromatography Methods 0.000 description 4
229940105402 brillant blue Drugs 0.000 description 4
210000002987 choroid plexus Anatomy 0.000 description 4
239000000147 enterotoxin Substances 0.000 description 4
231100000655 enterotoxin Toxicity 0.000 description 4
229960003180 glutathione Drugs 0.000 description 4
238000003119 immunoblot Methods 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000002751 oligonucleotide probe Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
238000012216 screening Methods 0.000 description 4
238000012163 sequencing technique Methods 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
101001057426 Archaeoglobus fulgidus (strain ATCC 49558 / DSM 4304 / JCM 9628 / NBRC 100126 / VC-16) Iron-sulfur flavoprotein AF_1896 Proteins 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
241000193163 Clostridioides difficile Species 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 3
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 3
230000003321 amplification Effects 0.000 description 3
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000000740 bleeding effect Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
235000011089 carbon dioxide Nutrition 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
239000003792 electrolyte Substances 0.000 description 3
210000005081 epithelial layer Anatomy 0.000 description 3
210000004907 gland Anatomy 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
230000002055 immunohistochemical effect Effects 0.000 description 3
210000002011 intestinal secretion Anatomy 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
229940045662 porcine thyroid Drugs 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
230000007017 scission Effects 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
241000894007 species Species 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
238000001262 western blot Methods 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
206010008631 Cholera Diseases 0.000 description 2
238000001712 DNA sequencing Methods 0.000 description 2
101710146739 Enterotoxin Proteins 0.000 description 2
241000701959 Escherichia virus Lambda Species 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
208000002720 Malnutrition Diseases 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
101800004192 Peptide P1 Proteins 0.000 description 2
108091036407 Polyadenylation Proteins 0.000 description 2
102100038803 Somatotropin Human genes 0.000 description 2
241000282887 Suidae Species 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000000211 autoradiogram Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
238000010276 construction Methods 0.000 description 2
210000001100 crypt cell Anatomy 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
210000000959 ear middle Anatomy 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
230000029142 excretion Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000007917 intracranial administration Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000001155 isoelectric focusing Methods 0.000 description 2
210000003140 lateral ventricle Anatomy 0.000 description 2
230000001071 malnutrition Effects 0.000 description 2
235000000824 malnutrition Nutrition 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
208000015380 nutritional deficiency disease Diseases 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 1
PZJFUNZDCRKXPZ-UHFFFAOYSA-N 2,5-dihydro-1h-tetrazole Chemical compound C1NNN=N1 PZJFUNZDCRKXPZ-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
208000005452 Acute intermittent porphyria Diseases 0.000 description 1
101100393868 Arabidopsis thaliana GT11 gene Proteins 0.000 description 1
206010048962 Brain oedema Diseases 0.000 description 1
101100245381 Caenorhabditis elegans pbs-6 gene Proteins 0.000 description 1
241000589875 Campylobacter jejuni Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108700010070 Codon Usage Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
102400000739 Corticotropin Human genes 0.000 description 1
101800000414 Corticotropin Proteins 0.000 description 1
208000014311 Cushing syndrome Diseases 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
208000004232 Enteritis Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
101000987581 Homo sapiens Perforin-1 Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
206010028665 Myxoedema Diseases 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
108010093625 Opioid Peptides Proteins 0.000 description 1
102000001490 Opioid Peptides Human genes 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
206010036182 Porphyria acute Diseases 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
206010037596 Pyelonephritis Diseases 0.000 description 1
108091034057 RNA (poly(A)) Proteins 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000242677 Schistosoma japonicum Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
241000607764 Shigella dysenteriae Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
241000607626 Vibrio cholerae Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000003674 animal food additive Substances 0.000 description 1
235000019728 animal nutrition Nutrition 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
230000002686 anti-diuretic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
229940124538 antidiuretic agent Drugs 0.000 description 1
239000003160 antidiuretic agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
239000000987 azo dye Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
210000003103 bodily secretion Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
235000012745 brilliant blue FCF Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000010367 cloning Methods 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000012303 cytoplasmic staining Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
235000021051 daily weight gain Nutrition 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
201000010064 diabetes insipidus Diseases 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
208000001848 dysentery Diseases 0.000 description 1
210000003890 endocrine cell Anatomy 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
230000004907 flux Effects 0.000 description 1
239000012520 frozen sample Substances 0.000 description 1
239000003629 gastrointestinal hormone Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000012151 immunohistochemical method Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000001153 interneuron Anatomy 0.000 description 1
210000002490 intestinal epithelial cell Anatomy 0.000 description 1
230000008991 intestinal motility Effects 0.000 description 1
230000003870 intestinal permeability Effects 0.000 description 1
238000010212 intracellular staining Methods 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
239000006166 lysate Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
208000004396 mastitis Diseases 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000012120 mounting media Substances 0.000 description 1
208000003786 myxedema Diseases 0.000 description 1
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
210000004412 neuroendocrine cell Anatomy 0.000 description 1
230000002644 neurohormonal effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000000422 nocturnal effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
239000003399 opiate peptide Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
150000002990 phenothiazines Chemical class 0.000 description 1
208000024335 physical disease Diseases 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
201000009395 primary hyperaldosteronism Diseases 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
INCIMLINXXICKS-UHFFFAOYSA-M pyronin Y Chemical compound [Cl-].C1=CC(=[N+](C)C)C=C2OC3=CC(N(C)C)=CC=C3C=C21 INCIMLINXXICKS-UHFFFAOYSA-M 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
210000005245 right atrium Anatomy 0.000 description 1
239000000523 sample Substances 0.000 description 1
210000002955 secretory cell Anatomy 0.000 description 1
238000012882 sequential analysis Methods 0.000 description 1
229940007046 shigella dysenteriae Drugs 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
150000005075 thioxanthenes Chemical class 0.000 description 1
-1 thyropropin Proteins 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
229940118696 vibrio cholerae Drugs 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000004260 weight control Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Polymers & Plastics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Addiction (AREA)
Food Science & Technology (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Pulmonology (AREA)
Immunology (AREA)
Animal Husbandry (AREA)

BG102280A 1995-08-24 1998-02-24 Пептиди на антисекреторен фактор регулиращи паталогичните промени на пропускливост BG63209B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9502936A SE508609C2 (sv)	1995-08-24	1995-08-24	Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
PCT/SE1996/001049 WO1997008202A1 (en)	1995-08-24	1996-08-23	Antisecretory factor peptides regulating pathological permeability changes

Publications (2)

Publication Number	Publication Date
BG102280A BG102280A (en)	1999-04-30
BG63209B1 true BG63209B1 (bg)	2001-06-29

Family

ID=20399269

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG102280A BG63209B1 (bg)	1995-08-24	1998-02-24	Пептиди на антисекреторен фактор регулиращи паталогичните промени на пропускливост

Country Status (28)

Country	Link
US (2)	US6344440B1 (cs)
EP (1)	EP0851876B1 (cs)
JP (2)	JP4040679B2 (cs)
KR (1)	KR100552947B1 (cs)
CN (1)	CN1171902C (cs)
AT (1)	ATE270305T1 (cs)
AU (1)	AU702589B2 (cs)
BG (1)	BG63209B1 (cs)
BR (1)	BR9610308A (cs)
CA (1)	CA2230111C (cs)
CZ (1)	CZ295444B6 (cs)
DE (2)	DE69632828T2 (cs)
DK (1)	DK0851876T3 (cs)
EA (1)	EA001201B1 (cs)
EE (1)	EE04501B1 (cs)
ES (1)	ES2118683T3 (cs)
HU (1)	HU224971B1 (cs)
IL (1)	IL123404A (cs)
NO (1)	NO320560B1 (cs)
NZ (2)	NZ316647A (cs)
PL (1)	PL188530B1 (cs)
PT (1)	PT851876E (cs)
RO (1)	RO120197B1 (cs)
SE (1)	SE508609C2 (cs)
SI (1)	SI0851876T1 (cs)
SK (1)	SK23698A3 (cs)
TR (1)	TR199800304T1 (cs)
WO (1)	WO1997008202A1 (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE508609C2 (sv) *	1995-08-24	1998-10-19	Rural Patent Svenska Ab	Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
SE9604251L (sv) *	1996-11-20	1997-12-22	Svenska Lantmaennen Riksfoerbu	Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) *	1998-12-17	2000-09-18	Rural Patent Svenska Ab	NASP-berikad äggula samt dess användning
AU5627000A (en) *	1999-06-21	2001-02-05	Inkine Pharmaceutical Company, Inc.	Angiocidin: a CYS-SER-VAL-THR-CYS-GLY specific tumor cell adhesion receptor
GB0322645D0 (en) *	2003-09-26	2003-10-29	Melacure Therapeutics Ab	Use of antisecretory factor peptides
KR20090037992A (ko)	2006-04-27	2009-04-17	란트만넨 아스-팍토르 아베	항분비 단백질의 추가적 의학 용도
SG171602A1 (en) *	2006-04-27	2011-06-29	Lantmaennen As Faktor Ab	Use of antisecretory factors for treating intraocular hypertension
PL2040734T3 (pl) *	2006-04-27	2012-04-30	Lantmaennen As Faktor Ab	Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału
RU2341981C2 (ru) *	2006-07-03	2008-12-27	Государственное учреждение Всероссийский научно-исследовательский институт пищевых ароматизаторов, кислот и красителей Российской академии сельскохозяйственных наук (ГУ ВНИИПАКК)	Комплексная пищевая добавка
US8901083B2 (en)	2008-11-25	2014-12-02	Temple University	Administration of angiocidin for the treatment of leukemia
JP5820277B2 (ja) *	2009-02-11	2015-11-24	ラントメネン・アーエス−ファクトール・アーベー	細胞取込を最適化するための抗分泌性因子（ａｆ）の使用
WO2017009004A1 (en)	2015-07-10	2017-01-19	Lantmännen As-Faktor Ab	Process for producing egg yolk with high content of af-16
US11407796B2 (en)	2016-07-18	2022-08-09	Lantmännen As-Faktor Ab	Antisecretory factor 17
WO2020002464A1 (en)	2018-06-28	2020-01-02	Lantmännen Medical Ab	Antisecretory factor for use in treatment and/or prevention of acute respiratory failure
CN112770643A (zh) *	2018-09-28	2021-05-07	兰特门内保健食品公司	包含麦芽化脱壳燕麦的可消耗产品
WO2020065091A1 (en)	2018-09-28	2020-04-02	Lantmännen Functional Foods Ab	A consumable product comprising malted wheat
EP4125984A1 (en)	2020-03-26	2023-02-08	Lantmännen Functional Foods AB	A consumable product comprising malted cereals for promoting recovery at physical activity
WO2026099453A1 (en)	2024-11-07	2026-05-15	Lantmännen Medical Ab	Af-16 or af-17 for acute treatment of brain oedema in patients with traumatic brain injury

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE508609C2 (sv) *	1995-08-24	1998-10-19	Rural Patent Svenska Ab	Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning

1995
- 1995-08-24 SE SE9502936A patent/SE508609C2/sv not_active IP Right Cessation
1996
- 1996-08-23 DE DE69632828T patent/DE69632828T2/de not_active Expired - Lifetime
- 1996-08-23 CN CNB961973005A patent/CN1171902C/zh not_active Expired - Lifetime
- 1996-08-23 AT AT96929619T patent/ATE270305T1/de active
- 1996-08-23 PT PT96929619T patent/PT851876E/pt unknown
- 1996-08-23 TR TR1998/00304T patent/TR199800304T1/xx unknown
- 1996-08-23 PL PL96325114A patent/PL188530B1/pl unknown
- 1996-08-23 EE EE9800055A patent/EE04501B1/xx not_active IP Right Cessation
- 1996-08-23 DK DK96929619T patent/DK0851876T3/da active
- 1996-08-23 NZ NZ316647A patent/NZ316647A/en not_active IP Right Cessation
- 1996-08-23 CZ CZ1998520A patent/CZ295444B6/cs not_active IP Right Cessation
- 1996-08-23 US US09/029,333 patent/US6344440B1/en not_active Expired - Lifetime
- 1996-08-23 KR KR1019980701343A patent/KR100552947B1/ko not_active Expired - Lifetime
- 1996-08-23 EP EP96929619A patent/EP0851876B1/en not_active Expired - Lifetime
- 1996-08-23 RO RO98-00364A patent/RO120197B1/ro unknown
- 1996-08-23 BR BR9610308-6A patent/BR9610308A/pt not_active IP Right Cessation
- 1996-08-23 DE DE0851876T patent/DE851876T1/de active Pending
- 1996-08-23 HU HU9900137A patent/HU224971B1/hu unknown
- 1996-08-23 CA CA2230111A patent/CA2230111C/en not_active Expired - Lifetime
- 1996-08-23 WO PCT/SE1996/001049 patent/WO1997008202A1/en not_active Ceased
- 1996-08-23 ES ES96929619T patent/ES2118683T3/es not_active Expired - Lifetime
- 1996-08-23 SK SK236-98A patent/SK23698A3/sk unknown
- 1996-08-23 IL IL12340496A patent/IL123404A/xx not_active IP Right Cessation
- 1996-08-23 JP JP51018597A patent/JP4040679B2/ja not_active Expired - Lifetime
- 1996-08-23 AU AU68932/96A patent/AU702589B2/en not_active Expired
- 1996-08-23 SI SI9630013T patent/SI0851876T1/xx unknown
- 1996-08-23 EA EA199800221A patent/EA001201B1/ru not_active IP Right Cessation
1998
- 1998-02-23 NO NO19980743A patent/NO320560B1/no not_active IP Right Cessation
- 1998-02-24 BG BG102280A patent/BG63209B1/bg unknown
1999
- 1999-08-20 NZ NZ337380A patent/NZ337380A/en not_active IP Right Cessation
2001
- 2001-11-26 US US09/991,792 patent/US20020099016A1/en not_active Abandoned
2007
- 2007-07-25 JP JP2007193054A patent/JP2008043331A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DE851876T1 (de)	1998-11-12
CN1171902C (zh)	2004-10-20
SE9502936L (sv)	1997-02-25
EP0851876A1 (en)	1998-07-08
SI0851876T1 (en)	2004-10-31
DE69632828T2 (de)	2005-07-14
US6344440B1 (en)	2002-02-05
AU6893296A (en)	1997-03-19
AU702589B2 (en)	1999-02-25
EE04501B1 (et)	2005-06-15
PT851876E (pt)	2004-10-29
ES2118683T3 (es)	2004-12-01
SE9502936D0 (sv)	1995-08-24
EE9800055A (et)	1998-08-17
RO120197B1 (ro)	2005-10-28
IL123404A (en)	2005-07-25
EA001201B1 (ru)	2000-12-25
KR100552947B1 (ko)	2006-04-21
JP4040679B2 (ja)	2008-01-30
PL325114A1 (en)	1998-07-06
SE508609C2 (sv)	1998-10-19
NZ337380A (en)	2001-02-23
HU224971B1 (en)	2006-04-28
BR9610308A (pt)	1999-12-21
NO320560B1 (no)	2005-12-19
JP2008043331A (ja)	2008-02-28
JPH11511972A (ja)	1999-10-19
NO980743L (no)	1998-04-16
NO980743D0 (no)	1998-02-23
PL188530B1 (pl)	2005-02-28
CZ52098A3 (cs)	1998-09-16
DK0851876T3 (da)	2004-10-25
HUP9900137A2 (hu)	1999-04-28
ATE270305T1 (de)	2004-07-15
IL123404A0 (en)	1998-09-24
BG102280A (en)	1999-04-30
SK23698A3 (en)	1998-12-02
CA2230111C (en)	2012-10-30
US20020099016A1 (en)	2002-07-25
EP0851876B1 (en)	2004-06-30
CZ295444B6 (cs)	2005-08-17
CN1208420A (zh)	1999-02-17
DE69632828D1 (de)	2004-08-05
KR19990044110A (ko)	1999-06-25
EA199800221A1 (ru)	1998-10-29
NZ316647A (en)	1999-10-28
CA2230111A1 (en)	1997-03-06
WO1997008202A1 (en)	1997-03-06
HK1018468A1 (en)	1999-12-24
TR199800304T1 (xx)	1998-05-21
HUP9900137A3 (en)	1999-11-29
ES2118683T1 (es)	1998-10-01

Publication	Publication Date	Title
JP2008043331A (ja)	2008-02-28	病理学的浸透性の変化を調節する抗分泌性因子ペプチド
Brigstock et al.	1997	Purification and Characterization of Novel Heparin-binding Growth Factors in Uterine Secretory Fluids: IDENTIFICATION AS HEPARIN-REGULATED M r10, 000 FORMS OF CONNECTIVE TISSUE GROWTH FACTOR
Johansson et al.	1995	Molecular Cloning and Expression of a Pituitary Gland Protein Modulating Intestinal Fluid Secretion (∗)
Saruta et al.	2005	Expression and localization of chromogranin A gene and protein in human submandibular gland
Kinoshita et al.	1997	Urine and plasma levels of uroguanylin and its molecular forms in renal diseases
NO332460B1 (no)	2012-09-24	Renset humant NOGO protein, fusjon- eller kimaert protein, isolert nukleinsyre, kloningsvektor, rekombinant celle, fremgangsmate for fremstilling av proteinet, samt anvendelse av proteinet for fremstilling av et medikament for behandling.
Johansson et al.	1997	Identification of an active site in the antisecretory factor protein
CN110088122A (zh)	2019-08-02	具有抗肥胖和抗糖尿病功效的肽及其用途
Leberer et al.	1989	Molecular cloning and expression of cDNA encoding the 53,000-dalton glycoprotein of rabbit skeletal muscle sarcoplasmic reticulum
PT98805B (pt)	1999-01-29	Processo de preparacao de uma nova proteina de ligacao ao factor de crescimento semelhante a insulina (igfbp-4)
IBRAHIM et al.	1999	Reproductive tract secretions and bull spermatozoa contain different clusterin isoforms that cluster cells and inhibit complement‐induced cytolysis
Aunis et al.	2000	Chromogranins: current concepts: structural and functional aspects
Ingleton et al.	2002	Calcium‐sensing receptors and parathyroid hormone‐related protein in the caudal neurosecretory system of the flounder (Platichthys flesus)
JPH03172183A (ja)	1991-07-25	脳因子発現系
PT99995B (pt)	1999-06-30	Processo de preparacao de uma nova proteina de ligacao ao factor de crescimento semelhante a insulina (igfbp-6)
WO2003102180A1 (fr)	2003-12-11	Nouveaux peptides avec activite de production de camp
Nock	2010	Development of an enzyme immunoassay and cellular function assays to probe the function of teneurin C-terminal associated peptide (TCAP)
JPS6229981A (ja)	1987-02-07	サルコフア−ガ・レクチンの構造遺伝子
HK1018468B (en)	2005-04-01	Antisecretory factor peptides regulating pathological permeability changes
Iguchi et al.	2004	Expression of secretin in porcine and rat central nervous system
AU4440302A (en)	2002-07-11	Heparin-binding growth factor (HBGF) polypeptides
HK1227790B (en)	2020-05-22	Cancer models and associated methods